Inverness Medical Innovations Inc has agreed to acquire HemoSense Inc in an all stock deal. Each holder of a share of HemoSense common stock will receive 0.274192 shares of Inverness common stock in the transaction, which represents a 37.5% premium, based on the average trading prices of both companies over the last 5 trading days.

Inverness is a manufacturer and marketer of laboratory diagnostic products. HemoSense is a point-of-care diagnostic company that manufactures and sells handheld blood coagulation systems for monitoring patients taking warfarin.